TOP-5 studies on disease treatment from 07.05.2026 to 07.12.2026
Low glycemic index diets and their impact on glycemic and lipid control in various populations: a systematic review and meta-analysis; How dietary interventions affect oral health; Neoadjuvant tislelizumab (anti-PD-1 antibody) combined with chemotherapy in patients with advanced epithelial ovarian cancer: the NAIVE study; Dual targeting of organelles by nanomaterials: therapeutic effects and toxicological consequences related to physicochemical properties; Dietary polyphenols as natural modulators of the NF-κB signaling pathway in inflammatory non-communicable diseases: a focus on cancer.
5. Low-carbohydrate diets with a low glycemic index and their impact on glycemic and lipid control in various populations: a systematic review and meta-analysis.
About the study.
The aim of the study was to evaluate the impact of low glycemic diets on glycemic and lipid profiles in various populations. The study included a comparison of the results of low glycemic diets with control diets.
Results.
Low glycemic diets significantly reduced fasting blood glucose levels (-0.19 mmol/L, p = 0.04), glycated hemoglobin (-0.22%, p < 0.01), and LDL cholesterol levels (-0.15 mmol/L, p < 0.01). Low glycemic diets also showed a trend towards increased HDL cholesterol levels and reduced fasting insulin, HOMA-IR, triglycerides, and total cholesterol.
4. How dietary interventions affect oral health: a systematic review.
About the study.
The aim of the study was to evaluate the impact of dietary interventions, such as fasting and caloric restriction, on oral health. The systematic review analyzed data on various diets and their effects on oral diseases.
Results.
Caloric restriction and intermittent fasting were generally associated with improvements in gum inflammation and metabolic parameters, without significant changes in the composition of the oral microbiota. Alternate-day fasting showed a positive effect on salivary gland function and inflammatory responses in preclinical models.
3. Neoadjuvant tislelizumab (anti-PD-1 antibody) combined with chemotherapy in patients with progressive epithelial ovarian cancer: the NAIVE study.
About the study.
The study aimed to evaluate the efficacy of neoadjuvant chemotherapy with tislelizumab compared to standard chemotherapy in patients with advanced epithelial ovarian cancer. The study included patients with stage IIIC-IV cancer according to FIGO classification.
Results.
NACI demonstrated numerically longer progression-free survival (27.2 vs. 21.8 months) and higher 1-year (92.3% vs. 83.3%) and 2-year (62.3% vs. 31.8%) progression-free survival rates. Better tumor responses were also observed, including a higher overall response rate (69.2% vs. 58.3%) and more R0 resections.
2. Dual targeting of organelles by nanomaterials: therapeutic effects and toxicological consequences related to physicochemical properties.
About the study.
This study examines the influence of the physicochemical properties of nanomaterials on their targeting to organelles and the associated therapeutic and toxicological effects. It discusses the mechanisms of interaction of nanomaterials with various organelles and factors affecting the efficacy of their targeted action.